Please assess the completion status of the following clinical trial:

Trial Title: Interest of the Peak of Reticulocytes in Chronic Hemodialysis Patients Treated by Mircera Hemodialysis Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age\> or equal to 18 years~* Patients on hemodialysis or hemodiafiltration for at least 3 months~* Patient treated monthly by Mircera® for at least one month~* Affiliate or enjoying a social security scheme~* Patients who received oral and written information about the study, with no objection to the use of personal data and having signed an informed consent form and written~Exclusion Criteria:~* Patient who refused to give his written consent to the study~* Patients treated with another Erythropoiesis stimulating agent~* Minor~* Pregnant or breastfeeding women~* Major under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reticera (Type: OTHER): A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) and 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).